Antihepatic Fibrosis Drugs in Clinical Trials
Open Access
- 24 August 2020
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 8 (4), 1-9
- https://doi.org/10.14218/jcth.2020.00023
Abstract
Liver fibrosis is not an independent disease. It refers to the abnormal proliferation of connective tissues in the liver caused by various pathogenic factors. Thus far, liver fibrosis has been considered to be associated with a set of factors, such as viral infection, alcohol abuse, non-alcoholic fatty liver disease, and autoimmune hepatitis, as well as genetic diseases. To date, clinical therapeutics for liver fibrosis still face challenges, as elimination of potential causes and conventional antifibrotic drugs cannot alleviate fibrosis in most patients. Recently, potential therapeutic targets of liver fibrosis, such as metabolism, inflammation, cell death and the extracellular matrix, have been explored through basic and clinical research. Therefore, it is extremely urgent to review the antihepatic fibrosis therapeutics for treatment of liver fibrosis in current clinical trials.Keywords
This publication has 64 references indexed in Scilit:
- Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver DiseasePLOS ONE, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosisProceedings of the National Academy of Sciences of the United States of America, 2012
- Pirfenidone inhibits carbon tetrachloride‐ and albumin complex‐induced liver fibrosis in rodents by preventing activation of hepatic stellate cellsClinical and Experimental Pharmacology and Physiology, 2009
- Dual Role of CCR2 in the Constitution and the Resolution of Liver Fibrosis in MiceThe American Journal of Pathology, 2009
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisJournal of Hepatology, 2009
- Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the LiverPhysiological Reviews, 2008
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2007
- A pilot study in patients with established advanced liver fibrosis using pirfenidoneGut, 2006
- Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocityThe Esophagus, 2003